.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,988,952

« Back to Dashboard

Details for Patent: 7,988,952

Title:Delivery of drug esters through an inhalation route
Abstract: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a method aspect of the present invention, a drug ester is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises a drug ester, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug ester degradation product. In a kit aspect of the present invention, a kit for delivering a drug ester through an inhalation route is provided which comprises: a) a thin coating of a drug ester composition and b) a device for dispensing said thin coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Princeton, NJ), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:Mar 27, 2008
Application Number:12/057,330
Claims:1. A condensation aerosol for delivery of drug ester, wherein the drug ester is an ester of a drug selected from the group consisting of aceclofenac, alclofenac, alminoprofen, amfenac, aspirin, benoxaprofen, bermoprofen, bromfenac, bufexamac, butibufen, bucloxate, carprofen, cinchophen, cinmetacin, clidanac, clopriac, clometacin, diclofenac, diflunisal, etodolac, fenclozate, fenoprofen, flutiazin, flurbiprofen, ibuprofen, ibufenac, indomethacin, indoprofen, ketoprofen, ketorolac, loxoprofen, meclofenamate, naproxen, oxaprozin, pirprofen, prodolic acid, salsalate, sulindac, tofenamate, tolmetincoated, apomorphine, baclofen, levodopa, carbidopa, and thioctate; wherein the aerosol is formed by heating a composition containing the drug ester coated on a solid support to produce a vapor and cooling the vapor to form a condensation aerosol comprising particles; wherein the particles comprise at least 10 percent by weight of the drug ester and less than 5 percent by weight of drug ester degradation products; and wherein the condensation aerosol has an MMAD between 0.2 and 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD between 1 and 3 microns.

3. The condensation aerosol according to claim 1, wherein the geometric standard deviation around the MMAD is less than 2.0.

4. The condensation aerosol according to claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.

5. The condensation aerosol according to claim 1, wherein the drug ester is an ester of a drug selected from the group consisting of indomethacin, ketoprofen, ketorolac, and apomorphine.

6. The condensation aerosol according to claim 5, wherein the condensation aerosol has an MMAD between 1 and 3 microns.

7. The condensation aerosol according to claim 5, wherein the geometric standard deviation around the MMAD is less than 2.0.

8. The condensation aerosol according to claim 5, wherein the composition further comprises a pharmaceutically acceptable excipient.

9. The condensation aerosol according to claim 5, wherein the drug ester is selected from the group consisting of indomethacin methyl ester, indomethacin ethyl ester, and indomethacin norcholine ester.

10. The condensation aerosol according to claim 5, wherein the drug ester is selected from the group consisting of ketoprofen methyl ester, ketoprofen ethyl ester, and ketoprofen norcholine ester.

11. The condensation aerosol according to claim 5, wherein the drug ester is selected from the group consisting of ketorolac methyl ester, ketorolac ethyl ester, and ketorolac norcholine ester.

12. The condensation aerosol according to claim 5, wherein the drug ester is apomorphine diacetate.

13. A method of producing a drug ester aerosol comprising: a. coating a composition containing the drug ester on a solid support, wherein the drug ester is an ester of a drug selected from the group consisting of aceclofenac, alclofenac, alminoprofen, amfenac, aspirin, benoxaprofen, bermoprofen, bromfenac, bufexamac, butibufen, bucloxate, carprofen, cinchophen, cinmetacin, clidanac, clopriac, clometacin, diclofenac, diflunisal, etodolac, fenclozate, fenoprofen, flutiazin, flurbiprofen, ibuprofen, ibufenac, indomethacin, indoprofen, ketoprofen, ketorolac, loxoprofen, meclofenamate, naproxen, oxaprozin, pirprofen, prodolic acid, salsalate, sulindac, tofenamate, tolmetincoated, apomorphine, baclofen, levodopa, carbidopa, and thioctate; b. heating the coated composition to form a vapor; and c. allowing the vapor to cool to produce a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of drug ester degradation products and wherein the condensation aerosol has an MMAD between 0.2 and 5 microns.

14. The method according to claim 13, wherein the condensation aerosol has an MMAD between 1 and 3 microns.

15. The method according to claim 13, wherein the coated composition comprises at least 10 percent by weight of the drug ester.

16. The method according to claim 13, wherein the composition further comprises a pharmaceutically acceptable excipient.

17. The method according to claim 13, wherein the drug ester is an ester of a drug selected from the group consisting of indomethacin, ketoprofen, ketorolac, and apomorphine.

18. The method according to claim 17, wherein the condensation aerosol has an MMAD between 1 and 3 microns.

19. The method according to claim 17, wherein the coated composition comprises at least 10 percent by weight of the drug ester.

20. The method according to claim 17, wherein the composition further comprises a pharmaceutically acceptable excipient.

21. The method according to claim 17, wherein the drug ester is selected from the group consisting of indomethacin methyl ester, indomethacin ethyl ester, and indomethacin norcholine ester.

22. The method according to claim 17, wherein the drug ester is selected from the group consisting of ketoprofen methyl ester, ketoprofen ethyl ester, and ketoprofen norcholine ester.

23. The method according to claim 17, wherein the drug ester is selected from the group consisting of ketorolac methyl ester, ketorolac ethyl ester, and ketorolac norcholine ester.

24. The method according to claim 17, wherein the drug ester is apomorphine diacetate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc